Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must be healthy boys or girls, 11-17 years of age~* Must be a virgin with no intention of becoming sexually active during the study period~* Must have been properly vaccinated against diphtheria, tetanus, pertussis and polio~Exclusion Criteria:~* Must not have received a vaccine against diphtheria, tetanus, pertussis and polio in the past 5 years~* Must not have received any prior human papillomavirus (HPV) vaccine

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Concomitant/CMF
- Group 2 (Type: EXPERIMENTAL): Non-Concomitant/CMF
- Group 3 (Type: EXPERIMENTAL): Concomitant/FMF
- Group 4 (Type: EXPERIMENTAL): Non-Concomitant/FMF

Based on this trial design, predict the completion outcome and termination type (if applicable).